Phase 1b trial of oral GLP-1 agonist HDM1002 shows weight reduction in Chinese adults with overweight/obesity
Can a new pill help with weight loss? Early trial shows promise
A phase 1b randomized controlled trial in Chinese adults with overweight/obesity without diabetes found greater weight reductions with oral …
A new oral weight-loss pill helped adults lose about 6 kilograms in just 28 days, showing early promise compared to a placebo.
GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysis
Could diabetes drugs help protect lungs? A new analysis of patient stories suggests a link
An analysis of 136 single-patient case reports from PubMed Open Access found that GLP-1 receptor agonist users had a lower risk of respirato…
Diabetes drugs linked to lower risk of serious lung problems in a new look at patient stories.
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
New-onset diabetes in adults over 50 associated with higher pancreatic cancer risk within 3 years
Could new diabetes after age 50 signal hidden pancreatic cancer?
A systematic review found individuals around 50 years and over with new-onset diabetes have a higher risk for pancreatic ductal adenocarcino…
New diabetes after age 50 might signal hidden pancreatic cancer, as patients face a higher risk of diagnosis within three years compared to …
Short-term liraglutide modulates proteins in obesity, showing weight-independent effects and myostatin suppression
Could a weight-loss drug work by changing your body's proteins?
A 5-week randomized trial in 20 adults with obesity found liraglutide 3 mg daily modulated 124 proteins, with 85% of effects persisting afte…
A weight-loss drug changed 124 blood proteins in a small study, with 85% of shifts not tied to weight loss, hinting at deeper body-wide effe…
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects
Can diabetes drugs help Wolfram syndrome? A new study looks at real-world use
A retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes found 35% had rec…
Doctors prescribed diabetes drugs to 35% of rare Wolfram syndrome patients, but records show no improvement in blood sugar, weight, or slowi…
Post hoc analysis links WHtR threshold to remission in obesity management with tirzepatide vs semaglutide
Could hitting specific weight targets help people feel better?
A post hoc analysis of the SURMOUNT-5 trial in participants with obesity found that 23.1%-33.9% on tirzepatide and 14.2%-20.7% on semaglutid…
People on tirzepatide who hit a waist-to-height ratio under 0.53 had more than double the odds of reaching remission compared to those who d…
Pilot qualitative study explores pathways and acceptability of cash transfers for low-income patients with hypertension or diabetes
Could giving cash to patients with high blood pressure or diabetes help their health?
A pilot RCT qualitative sub-study of 100 low-income Pennsylvania Medicaid patients with hypertension or diabetes explored an unconditional c…
Giving cash to low-income patients with high blood pressure or diabetes helped them cover basic needs, reducing stress and making it easier …
Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration
First CRISPR gene therapy approved for blood disorders, with broader research underway
A systematic review of clinical trials registered at clinicaltrials.gov found the first CRISPR-Cas9 therapy obtained FDA approval in late 20…
The first CRISPR gene therapy is approved for sickle-cell anemia and β-thalassemia, with ongoing trials exploring its use for cancer and inf…
GLP-1 receptor agonists reduce new-onset heart failure risk in patients with diabetes or obesity
Could diabetes drugs also help protect the heart from failure?
A meta-analysis of 6 RCTs involving 52,752 participants without heart failure found GLP-1 receptor agonists decreased new-onset HF risk (HR=…
Diabetes drugs like semaglutide lower the risk of new heart failure by 23% in people with Type 2 diabetes or obesity, offering heart protect…
GLP-1RAs Show No Significant Motor Benefit in Parkinson's Disease Meta-Analysis
GLP-1 drugs show no clear motor benefit for Parkinson's in analysis of 708 patients
A meta-analysis of 5 RCTs involving 708 patients with Parkinson's disease found no statistically significant benefit of GLP-1 receptor agoni…
A new analysis of 708 Parkinson's patients found that diabetes drugs called GLP-1s offered no clear benefit for movement symptoms and caused…
GLP-1RAs associated with improved walking distance in diabetes with PAD, but limb event evidence uncertain
GLP-1 drugs linked to better walking distance in diabetes patients with leg artery disease
A meta-analysis of 7 studies (107,092 adults with type 2 diabetes and PAD) found GLP-1RAs were associated with improved walking distance in …
GLP-1 diabetes drugs linked to better walking distance in people with leg artery disease, based on analysis of seven studies involving over …